Trypanosoma cruzi: sensitivity to selective drugs in phylogenetically unrelated stocks.

Abstract Laurent, J-P., and Swindle, J. 2000. Trypanosoma cruzi: Sensitivity to selective drugs in phylogenetically unrelated stocks. Experimental Parasitology 94, 60–61.

[1]  M. Tibayrenc,et al.  Trypanosoma cruzi: impact of clonal evolution of the parasite on its biological and medical properties. , 1998, Experimental parasitology.

[2]  G. Buck,et al.  The transcription promoter of the spliced leader gene from Trypanosoma cruzi. , 1997, Gene.

[3]  M. Tibayrenc,et al.  Impact of clonal evolution on the biological diversity of Trypanosoma cruzi , 1997, Parasitology.

[4]  O. Fernandes,et al.  DNA markers define two major phylogenetic lineages of Trypanosoma cruzi. , 1996, Molecular and biochemical parasitology.

[5]  J. Swindle,et al.  The calmodulin-ubiquitin (CUB) genes of Trypanosoma cruzi are essential for parasite viability. , 1996, Molecular and biochemical parasitology.

[6]  J. Boothroyd,et al.  Molecular approaches to parasitology , 1995 .

[7]  M. Tibayrenc.  Population genetics of parasitic protozoa and other microorganisms. , 1995, Advances in parasitology.

[8]  E. Bakker.  Aminoglycoside and aminocyclitol antibiotics: hygromycin B is an atypical bactericidal compound that exerts effects on cells of Escherichia coli characteristics for bacteriostatic aminocyclitols. , 1992, Journal of general microbiology.

[9]  S. G. Andrade.  Influence of Trypanosoma cruzi strain on the pathogenesis of chronic myocardiopathy in mice. , 1990, Memorias do Instituto Oswaldo Cruz.

[10]  F. Ayala,et al.  Natural populations of Trypanosoma cruzi, the agent of Chagas disease, have a complex multiclonal structure. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Dvorak.  The natural heterogeneity of trypanosoma cruzi: Biological and medical implications , 1984, Journal of cellular biochemistry.